After finishing at $27.42 in the prior trading day, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed at $28.28, up 3.14%. In other words, the price has increased by $+0.86 from its previous closing price. On the day, 3721799 shares were traded. ARWR stock price reached its highest trading level at $29.01 during the session, while it also had its lowest trading level at $27.00.
Ratios:
Our goal is to gain a better understanding of ARWR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.73 and its Current Ratio is at 3.73. In the meantime, Its Debt-to-Equity ratio is 2.45 whereas as Long-Term Debt/Eq ratio is at 2.42.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on December 04, 2023, initiated with a Buy rating and assigned the stock a target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’24 when Myszkowski Kenneth Allen sold 40,000 shares for $35.19 per share. The transaction valued at 1,407,600 led to the insider holds 400,600 shares of the business.
Anzalone Christopher Richard sold 57,499 shares of ARWR for $1,860,019 on Jan 31 ’24. The Chief Executive Officer now owns 3,715,048 shares after completing the transaction at $32.35 per share. On Jan 12 ’24, another insider, Hamilton James C, who serves as the Chief Discovery/Trans Medicine of the company, sold 7,940 shares for $36.89 each. As a result, the insider received 292,904 and left with 210,851 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 3.51B and an Enterprise Value of 3.40B. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.28 while its Price-to-Book (P/B) ratio in mrq is 18.95. Its current Enterprise Value per Revenue stands at 18.73 whereas that against EBITDA is -12.68.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $42.48, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is 32.72, while the 200-Day Moving Average is calculated to be 30.42.
Shares Statistics:
The stock has traded on average 1.65M shares per day over the past 3-months and 1.64M shares per day over the last 10 days, according to various share statistics. A total of 123.90M shares are outstanding, with a floating share count of 117.66M. Insiders hold about 5.03% of the company’s shares, while institutions hold 62.61% stake in the company. Shares short for ARWR as of Feb 29, 2024 were 8.84M with a Short Ratio of 5.34, compared to 7.72M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.13% and a Short% of Float of 8.37%.
Earnings Estimates
Its stock is currently analyzed by 12 different market analysts. On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of $3.27 and a low estimate of -$0.95, while EPS last year was $0.45. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.24 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$1.26 and -$4.07 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$2.63, with 12 analysts recommending between -$1.46 and -$3.98.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $302M, while the lowest revenue estimate was $53.55M, resulting in an average revenue estimate of $139.03M. In the same quarter a year ago, actual revenue was $240.74M, down -42.20% from the average estimate.
